Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 353-363

  Nappi, Jean M ^a   Sieg, Adam ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Aldosterone receptor antagonists; Eplerenone; Spironolactone; Systolic heart failure

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; CARDIOVASCULAR AGENT;

CHRONIC DISEASE; DRUG ANTAGONISM; HEART FAILURE; HUMAN; METABOLISM; PATIENT SELECTION; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; HEART FAILURE; HUMANS; PATIENT SELECTION; RECEPTORS, ALDOSTERONE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 80055092820     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S13779     Document Type: Review

References (59)

1. Pitt B, Zannad F, Remme WJ, et al; RALES Study Group. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
2. White PC. Disorders of aldosterone biosynthesis and action. N Engl J Med. 1994;331:250-258.
3. Brown NJ. Eplerenone: Cardiovascular protection. Circulation. 2003; 107:2512-2518.
4. Ganguly A. Atrial natriuretic peptide-induced inhibition of aldosterone secretion: A quest for mediator(s). Am J Physiol. 1992;263:e181-e194.
5. Nushiro N, Ito S, Carretero OA. Renin release from microdissected, superficial, midcortical, and juxtamedullary afferent arterioles in rabbits. Kidney Int. 1990;38;426-431.
6. Ichikawi I. Angiotensin actions in the kidney: Renewed insight into the old hormone. Kidney Int. 1991;40:583-596.
7. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45: 205-251.
8. Berridge MJ. Inositol trisphosphate and calcium signaling. Nature. 1993;361:315-325.
9. Rabinowitz L. Aldosterone and potassium homeostasis. Kidney Int. 1996;49:1738-1742.
10. Himathongkam T, Dluhy RG, Williams GH. Potassium-aldosteronerenin inter relationships. J Clin Endocrinol Metab. 1975;41:153-159.
11. Young DB, Smith MJ Jr, Jackson TE, Scott RE. Multiplicative interaction between angiotensin II and K concentration in stimulation of aldosterone. Am J Physiol. 1984;247(3 Pt 1):E328-E335.
12. Shier DN, Kusano E, Stoner GD, Franco-Saenz R, Mulrow PJ. Production of renin, angiotensin II and aldosterone by adrenal explant cultures: Response to potassium and converting enzyme inhibition. Endocrinology. 1989;125:486-491.
13. - cotransporter abundance: Role of aldosterone. J Am Soc Nephrol. 2001;12:1335-1341.
14. Bastl CP, Hayslett JP. The cellular action of aldosterone in target epithelia. Kidney Int. 1992;42;250-264.
15. Horisberger JD, Rossier BC. Aldosterone regulation of gene transcription leading to control of ion transport. Hypertension. 1992;19:221-227.
16. Laragh JH. Aldosterone in fluid and electrolyte disorders: Hyper and hypoaldosteronism. J Clin Dis. 1960;11:292-318.
17. Laragh JH. Cirrhosis for renal-adrenal interaction from studies in hypertension and in failure: Vasopressin, aldosterone, and angiotensin II: further evidence hormones and the pathogenesis of congestive heart. Circulation. 1962;25:1015-1023.
18. O'Neil RG, Hayhurst RA. Sodium-dependent modulation of the renal Na-K-ATPase: Influence of mineralocorticoids on the cortical collecting duct. J Membr Biol. 1985;8:169-179.
19. Brilla CG, Weber KT. Mineral ocorticoid excess, dietarysodium and myocardial fibrosis. J Lab Clin Med. 1992;120:893-901.
20. Brilla CG, Matsubara LS, Weber KT. Anti-aldosteronetreatment and the prevention of myocardial fibrosis in primary and secondary ldosteronism. J Mol Cell Cardiol. 1993;25:563-575.
21. Robert V, Silvestre JS, Charlemagne D, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension. 1995;26 (6 Pt 1):971-978.
22. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578-2583.
23. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcarye C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: Role in aldosterone-salt-induced fibrosis. Hypertension. 1999;33:981-986.
24. Sun Y, Ramiers F, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 1997;35:138-147.
25. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504-510.
26. Harda E, Yoshimura M, Yasue H, et al. Aldosterone induces angiotensinconverting enzyme gene expression in cultured neonatal rat cardiocytes. Circulation. 2001;104:137-139.
27. Carey RM. Aldosterone and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2010;17:194-198.
28. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Resp. 2005;97:434-442.
29. Michel F, Amboisine ML, Duriez M, Delcayre C, Levy Bi, Silvestre JS. Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation. 2004;109:1933-1937.
30. Min LJ, Mogi M, Iwanami J, et al. Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence. Cardiovasc Res. 2007;76:506-516.
31. Chai W, Garrelds IM, de Vries R, Batenburg WW, van Kats JP, Danser AH. Nongenomic effects of aldosterone in the human heart: Interaction with angiotensin II. Hypertension. 2005;46:701-706.
32. Romagni P, Rossi F, Guerrini L, Quirini C, Santiemma V. Aldosterone induces contraction of the resistance arteries in man. Athero sclerosis. 2003;166:345-349.
33. Fujita M, Minamino T, Asanuma H, et al. Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts. Hypertension. 2005;46:113-117.
34. Struthers A, Krum H, Williams GH. A comparison of the aldosteroneblocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31:153-158.
35. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697.
36. Tait JF, Little B, Tait SAS, Flood C, Bougas J. Splanchnic extraction and clearance of aldosterone in subjects with minimal and marked cardiac dysfunction. J Clin Endocrinol Metab. 1965;25:219-228.
37. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L; CONSENSUS Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730-1736.
38. Sato A, Funder JW, Saruta T. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens. 1999;12(9 Pt 1):867-873.
39. Vogt B, Burnier M. Aldosterone and cardiovascular risk. Curr Hypertens Rep. 2009;11:450-455.
40. Overdiek H, Hermens W, Merkus F. New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther. 1985;38:469-474.
41. Gardiner P, Schrode K, Quinlan D, et al. Spironolactone metabolism: Steady-state serum levels of sulfur-containing metabolites. J Clin Pharmacol. 1989;29:342-347.
42. Sadee W, Dagcioglu M, Schroder R. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther. 1973;185:686-695.
43. Inspra [Product information]. Chicago, IL: GD Searle; 2003.
44. Abshagen U, Rennekamp H, Luszpinski G. Pharmacokinetics of spironolactone in man. Naunyn Schmie Debergs Arch Pharmacol. 1976;296:37-45.
45. Ravis WR, Reid S, Sica DA, Tolbert DS. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol. 2005;45:810-821.
46. Zannad F, McMurray J, Krum H, et al; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
47. Jackson L, Branch R, Levine D, Ramsay L. Elimination of canrenone in congestive heart failure and chronic liver disease. Eur J Clin Pharmacol. 1977;11:177-179.
48. Horisberger JD, Giebisch G. Potassium-sparing diuretics. Ren Physiol. 1987;10:198-220.
49. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987; 60:820-825.
50. Pitt B, Remme W, Zannad F, et al; EPHESUS Study Group. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
51. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709-716.
52. Dargie HJ; CAPRICORN Study Group. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction. Lancet. 2001;357:1385-1390.
53. Dastidar AG. Eplerenone in mild heart failure. N Engl J Med. 2011: 364:1370-1372.
54. Lindenfeld J, Albert NM, Boehmer JP, et al. Executive summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16:e1-e194.
55. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: A systematic review of randomized clinical trials. Eur Heart J. 2009;30:469-477.
56. Boccanelli A, Mureddu GF, Cacciatore G, et al; AREA IN-CHF Study Group. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): Final results. Eur J Heart Fail. 2009;11:68-76.
57. Udelson JE, Feldman AM, Greenberg B, et al. Randomized, doubleblind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail. 2010;3:347-353.
58. Pascual-Figal DA, Sanchez-Mas J, Januzzi JL. Eplerenone in mild heart failure. N Engl J Med. 2011;364:1370.
59. Montague BT, Ouellette JR, Buller GK. Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol. 2008;3:324-330.